Back to News
Market Impact: 0.15
Dong-A ST Demonstrates Preclinical Potential of Topical Icotrokinra Formulation for Psoriasis
Source: Business Wire
Healthcare & Biotech
Dong-A ST presented preclinical data at AAPS PharmSci 360 2026 on developing icotrokinra as a topical psoriasis treatment. The article provides no efficacy results, development timeline, or financial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- J&J's potential 'game-changer' drug — plus, what Microsoft's mass buyouts mean
- Cramer: I asked some tech insiders what to buy. They surprisingly said this drug stock
- The excitement around Moderna’s cancer vaccine is cooling. Here’s why.
- Moderna CEO Sees Cancer Vaccines Working Beyond Melanoma
- Bottoms Says Georgia Needs Pause on New Data Centers
- Genmab shares jump 13% on colorectal cancer drug trial results